Charenton-le-Pont, France

Franck Lestournelle

This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignee: Essilor International. Active years: 2020.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Franck Lestournelle: Innovator in Optical Technology

Introduction

Franck Lestournelle is a notable inventor based in Charenton-le-Pont, France. He has made significant contributions to the field of optical technology, particularly in the development of products that protect users from harmful light exposure.

Latest Patents

Lestournelle holds a patent for an innovative optical article designed to protect the eyes from phototoxic blue light. This optical article features a substrate with a front main face and a rear main face. It has a colorimetric coefficient b* that is lower than or equal to 4, a relative light transmission factor in the visible spectrum Tv that is higher than or equal to 87%, and it blocks at least 8% of light with wavelengths ranging from 420 to 450 nm. This invention is crucial for safeguarding users' eyes from the adverse effects of blue light exposure.

Career Highlights

Franck Lestournelle is currently associated with Essilor International, a leading company in the optical industry. His work focuses on creating advanced optical solutions that enhance visual comfort and health.

Collaborations

Lestournelle collaborates with talented professionals in his field, including Aude Carrega and Armel Jimenez. Their combined expertise contributes to the innovative projects at Essilor International.

Conclusion

Franck Lestournelle's work in optical technology exemplifies the importance of innovation in protecting eye health. His contributions, particularly in developing solutions against blue light exposure, highlight the ongoing advancements in this critical area.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…